Convatec GroupCNVVF 77 Net Margin % is 5.58% as of Dec. 2025, which is 7% below its 10-year median of 6.01. GuruFocus rates CNVVF with a GF Score™ of 77/100 and a GF Value™ of $3.08 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Convatec Group ranks better than 65.73% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Convatec Group's Net Income for the
six
months ended in Dec. 2025 was $70 Mil. Convatec Group's Revenue for the
six
months ended in Dec. 2025 was $1,259 Mil. Therefore, Convatec Group's net margin for the quarter that ended in Dec. 2025 was 5.58%.
The historical rank and industry rank for Convatec Group's Net Margin % or its related term are showing as below:
CNVVF'
s Net Margin % Range Over the Past 10 Years
Min: -12.01 Med: 6.01 Max: 12.1
Current: 7.16
CNVVF's Net Margin % is ranked better than 65.73% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs CNVVF: 7.16
Convatec Group (OTCPK:CNVVF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Convatec Group Net Margin % Related Terms
Convatec Group Net Margin % Historical Data
* Premium members only.
The historical data trend for Convatec Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Convatec Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Convatec Group Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Convatec Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where Convatec Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Convatec Group (CNVVF) has a Net Margin % of 5.58% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Convatec Group and its competitors. This is near median its historical median of 6.01. According to the industry distribution chart, Convatec Group ranks #280 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 34.3%.
Is Convatec Group's Net Margin % too high?
Convatec Group's current Net Margin % of 5.58% is near median its 10-year median of 6.01. The Medical Devices & Instruments industry median Net Margin % is 2.07. Convatec Group's value of 5.58% is 169.6% above this industry median. Based on the distribution chart, Convatec Group ranks #280 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Convatec Group has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Convatec Group's Net Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Convatec Group ranks #280 out of 817 companies for Net Margin %. This puts Convatec Group in the upper half of its industry. The industry median Net Margin % is 2.07. Convatec Group's value of 5.58% is 169.6% above this benchmark. While the company's 10-year median is 6.01 vs. the industry median of 2.07, Convatec Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Convatec Group's current Net Margin % of 5.58% is 169.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Convatec Group and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Convatec Group's current Net Margin % is 5.58%, which is near median its own 10-year median of 6.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Convatec Group stock overvalued right now?
Based on GuruFocus' analysis, Convatec Group (CNVVF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.08, compared to a current price of $2.73 — trading 11.4% below its estimated fair value. The current Net Margin % is 5.58%, which is near median its 10-year median of 6.01 and 169.6% above the Medical Devices & Instruments industry median of 2.07. Convatec Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Convatec Group (CNVVF), the current Net Margin % is 5.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Convatec Group (CNVVF) Overvalued in 2026?
Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued.
The current stock price of $2.73 is trading 11.4% below its estimated GF Value™ of $3.08.
GuruFocus considers Convatec Group to be Modestly Undervalued.
Key valuation signals for CNVVF:
Net Margin %: 5.58% (near median its 10-year median of 6.01)
GF Value™: $3.08 vs. price of $2.73 (11.4% below fair value)
Industry Position: 169.6% above the Medical Devices & Instruments median (#280 of 817)
No single metric tells the full story. See the CNVVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
77GF Score
Get the complete analysis for CNVVF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNVVF has been successfully added to your 
